-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S65sCrFVPx42cJEFq+t7dNrTjND8Txo+7IxpTKQvpfrOxpb/KnQBMi5hIB7Zud6t TGSE0vZOc1W9pkIjRP1fjg== 0000950123-04-001351.txt : 20040206 0000950123-04-001351.hdr.sgml : 20040206 20040206170803 ACCESSION NUMBER: 0000950123-04-001351 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040206 EFFECTIVENESS DATE: 20040206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIORELIANCE CORP CENTRAL INDEX KEY: 0001036629 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 521541583 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-22879 FILM NUMBER: 04575119 BUSINESS ADDRESS: STREET 1: C/O MICROBIOLOGICAL ASSOCIATES INC STREET 2: 9900 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 3017381000 MAIL ADDRESS: STREET 1: C/O MICROBIOLOGICAL ASSOCIATES INC STREET 2: 9900 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 15-12G 1 y93941e15v12g.htm BIORELIANCE CORP. BIORELIANCE CORP.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 0-22879

BIORELIANCE CORPORATION

(Exact name of registrant as specified in its charter)

14920 Broschart Road, Rockville, Maryland 20850          (301) 738-1000

(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

Common Stock, $.01 par value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

     Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

                 
Rule 12g-4(a)(1)(i)   x   Rule 12h-3(b)(1)(i)   x    
Rule 12g-4(a)(1)(ii)   o   Rule 12h-3(b)(1)(ii)   o    
Rule 12g-4(a)(2)(i)   o   Rule 12h-3(b)(2)(i)   o    
Rule 12g-4(a)(2)(ii)   o   Rule 12h-3(b)(2)(ii)   o    
        Rule 15d-6   o    

     Approximate number of holders of record as of the certification or notice date: One (1)

     Pursuant to the requirements of the Securities Exchange Act of 1934, BioReliance Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

         
Date: February 6, 2004   By:   /s/ Capers McDonald
       
    Name: Capers McDonald
    Title: President and Chief Executive Officer

Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

-----END PRIVACY-ENHANCED MESSAGE-----